Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function

Clinical Cancer Research

Volumn 13, Issue 16, 2007, Pages 4660-4663

  Rubin, Jeffrey S ^a   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; COMPLEMENTARY DNA; FRIZZLED RELATED PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN; SCATTER FACTOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; WNT PROTEIN;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; EMBRYO DEVELOPMENT; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CARCINOMA; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

CARCINOMA, RENAL CELL; GLYCOPROTEINS; HUMANS; KIDNEY NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34548092935     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1077     Document Type: Review

References (25)

1. Gumz ML, Zou H, Kreinest PA, et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007;13:4740-9.
2. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-80.
3. Rubin JS, Barshishat-Kupper M, Feroze-Merzoug F, Xi ZF. Secreted WNT antagonists as tumor suppressors: pro and con. Front Biosci 2006;11:2093-105.
4. Finch PW, He X, Kelley MJ, et al. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci U S A 1997;94:6770-5.
5. Leyns L, Bouwmeester T, Kim SH, Piccolo S, De Robertis EM. Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 1997;88:747-56.
6. Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006;12:6989-97.
7. Dahl E, Wiesmann F, Woenckhaus M, et al. Frequent loss of SFRP1 expression in multiple human solid tumours: associationwith aberrant promoter methylation in renal cell carcinoma. Oncogene 2007.
8. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007;13:671-9s.
9. Dressler GR. The cellular basis of kidney development. Annu Rev Cell Dev Biol 2006;22:509-29.
10. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004;6:497-506.
11. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22.
12. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002;1:279-88.
13. Seifert JR, Mlodzik M. Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet 2007;8:126-38.
14. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
15. Klopocki E, Kristiansen G, Wild PJ, et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004;25:641-9.
16. Kurose K, Sakaguchi M, Nasu Y, et al. Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol 2004;171:1314-8.
17. Abarzua F, Sakaguchi M, Takaishi M, et al. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res 2005;65:9617-22.
18. Russell RC, Ohh M. The role of VHL in the regulation of E-cadherin: a new connection in an old pathway. Cell Cycle 2007;6:56-9.
19. Lee JM, Dedkar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development and disease. J Cell Biol 2006;172:973-81.
20. Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the β-catenin pathway. Mol Cell Biol 2001;21:5857-68.
21. Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. Essential role of BCL9-2 in the switch between β-catenin's adhesive and transcriptional functions. Genes Dev 2004;18:2225-30.
22. Kaelin WG, Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-82.
23. Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic h-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A 2006;103:14531-6.
24. Kaidi A, Williams AC, Paraskeva C. Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007;9:210-7.
25. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601-8.